Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.85 |
| ▸ | BLVRB | P30043 | 2/20 | 0.85 |
| ▸ | PDE4A | P27815 | 1/20 | 0.85 |
| ▸ | KDR | P35968 | 1/20 | 0.85 |
| ▸ | HTT | P42858 | 1/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.80 |
| ▸ | APP | P05067 | 1/20 | 0.80 |
| ▸ | THRB | P10828 | 1/20 | 0.80 |
| ▸ | RECQL | P46063 | 1/20 | 0.80 |
| ▸ | BLM | P54132 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.69 |
| ▸ | PHLPP2 | Q6ZVD8 | 2/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | TSHR | P16473 | 2/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15339774 | 1.00 | MEN1 (0.85) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL137146 | 1.00 | MEN1 (0.85) | MEN1KMT2ABLVRBPDE4AKDR | |
| SCHEMBL28847216 | 0.98 | MEN1 (0.82) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL29861404 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL29385751 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL2628413 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL25119 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL25118 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL29378994 | 0.92 | MEN1 (1.00) | MEN1KMT2ABLVRBPDE4AKDR | |
| Olsalazine SCHEMBL29769 | 0.90 | MEN1 (0.96) | MEN1KMT2ABLVRBPDE4AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7563753-B2 | Cleaning solution for removing photoresist | HYNIX SEMICONDUCTOR INC. (KR) | 2009-07-21 | — | — | US | claimed |
| EP-0738152-B1 | USE OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES AS COLON CANCER CHEMOPREVENTATIVE AND CHEMOTHERAPEUTIC AGENTS | SALIX PHARMACEUTICALS INC (US) | 2005-11-02 | — | — | EP | claimed |
| US-5905073-A | ANTICARCINOGENIC AGENTS | SALIX PHARMACEUTICALS, INC. (US) | 1999-05-18 | — | — | US | claimed |
| US-5498608-A | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents | SALIX PHARMACEUTICALS (US) | 1996-03-12 | — | — | US | claimed |
| US-4412992-A | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith | BIOREX LABORATORIES LIMITED (GB) | 1983-11-01 | — | — | US | claimed |
| US-20230321096-A1 | COMPOSITION FOR IMPROVING, PREVENTING OR TREATING MUSCULAR DISORDERS INCLUDING SULFONAMIDE-BASED COMPOUNDS | THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-2096912-B1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES | SALIX PHARMACEUTICALS INC (US) | 2018-05-30 | — | — | EP | disclosed |
| EP-2563117-B1 | FORMULATIONS AND USES OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES FOR THE TREATMENT OF MALES | SALIX PHARMACEUTICALS LTD (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170333458-A1 | PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS | TECHNOLAS PERFECT VISION GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| EP-2978416-B1 | PHARMACEUTICAL FORMULATION COMPRISING PHOSPHATIDYLCHOLINE FOR THE TREATMENT OF ULCERATIVE COLITIS | LIPID THERAPEUTICS GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-20160120886-A1 | PREVENTION, TREATMENT, AND AMELIORATION OF RADIATION INDUCED ENTERITIS | Salix Pharmaceuticals, Ltd | 2016-05-05 | — | — | US | disclosed |
| US-20160045523-A1 | PHARMACEUTICAL FORMULATION COMPRISING PHOSPHATIDYLCHOLINE FOR THE TREATMENT OF ULCERATIVE COLITIS | LIPID THERAPEUTICS GMBH (DE) | 2016-02-18 | — | — | US | disclosed |
| US-5498608-A | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents | SALIX PHARMACEUTICALS (US) | 1996-03-12 | — | — | US | disclosed |
| US-5498608-A | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents | SALIX PHARMACEUTICALS (US) | 1996-03-12 | — | — | US | disclosed |
| WO-1995018622-A1 | USE OF 2-HYDROXY-5-PHENYLAZOBENZOIC ACID DERIVATIVES AS COLON CANCER CHEMOPREVENTATIVE AND CHEMOTHERAPEUTIC AGENTS | SALIX PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0203122-B1 | A PROCESS FOR PREPARING P-AMINO PHENOLS BY ELECTROLYSIS | FARMACEUTISK LABORATORIUM FERRING A/S (DK) | 1989-04-26 | — | — | EP | disclosed |
| US-4670112-A | USING P-PHENYLAZOPHENALS | FARMACEUTISK LABORATORIUM FERRING A/S (DK) | 1987-06-02 | — | — | US | disclosed |
| EP-0203122-A1 | A PROCESS FOR PREPARING p-AMINO PHENOLS BY ELECTROLYSIS. | FERRING FARMA LAB (DK) | 1986-12-03 | — | — | EP | disclosed |
| WO-1986003194-A1 | A PROCESS FOR PREPARING p-AMINO PHENOLS BY ELECTROLYSIS | FARMACEUTISK LABORATORIUM FERRING A/S (DK) | 1986-06-05 | — | — | WO | disclosed |
| US-4412992-A | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith | BIOREX LABORATORIES LIMITED (GB) | 1983-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321096-A1 | COMPOSITION FOR IMPROVING, PREVENTING OR TREATING MUSCULAR DISORDERS INCLUDING SULFONAMIDE-BASED COMPOUNDS | PHF20, MYH10, MYOF | MEN1 4446/4885KMT2A 487/4885BLVRB 4147/4885 |
| US-20160045523-A1 | PHARMACEUTICAL FORMULATION COMPRISING PHOSPHATIDYLCHOLINE FOR THE TREATMENT OF ULCERATIVE COLITIS | LPAR1, FFAR1, LPAR2 | MEN1 4022/4885KMT2A 3450/4885BLVRB 2420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.